Guardant Health Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Guardant Health stock.
View analyst ratings for Guardant Health or view top-rated stocks.

Wall Street analysts have given Guardant Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Guardant Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Guardant Health.

Guardant Health, Inc. (NASDAQ:GH) posted its earnings results on Thursday, May, 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.82) by $0.33. The business earned $78.67 million during the quarter, compared to analysts' expectations of $74.28 million. Guardant Health had a negative trailing twelve-month return on equity of 30.60% and a negative net margin of 112.70%. The business's revenue was up 16.5% on a year-over-year basis. During the same period last year, the firm posted ($0.29) earnings per share.
View Guardant Health's earnings history.

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GH shares have increased by 92.1% and is now trading at $120.94.
View which stocks have been most impacted by COVID-19.

Guardant Health updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $360 million-$370 million, compared to the consensus revenue estimate of $367.76 million.

11 brokers have issued twelve-month price targets for Guardant Health's stock. Their forecasts range from $135.00 to $195.00. On average, they expect Guardant Health's stock price to reach $167.50 in the next twelve months. This suggests a possible upside of 38.5% from the stock's current price.
View analysts' price targets for Guardant Health or view top-rated stocks among Wall Street analysts.

52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Guardant Health include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Natera (NTRA), Invitae (NVTA), CareDx (CDNA), Burning Rock Biotech (BNR), Veracyte (VCYT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Genetron (GTH), RadNet (RDNT), DermTech (DMTK), Renalytix AI (RNLX), Personalis (PSNL) and Celcuity (CELC).
View all of GH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), The Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Guardant Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include SB Investment Advisers UK Ltd. (6.11%), BlackRock Inc. (5.34%), Morgan Stanley (4.38%), Clearbridge Investments LLC (3.02%), Viking Global Investors LP (2.89%) and Jennison Associates LLC (2.70%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends for Guardant Health.

GH stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Viking Global Investors LP, Morgan Stanley, Jennison Associates LLC, Lord Abbett & CO. LLC, JPMorgan Chase & Co., SB Investment Advisers UK Ltd., and Clearbridge Investments LLC. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health or view top insider-selling stocks.

GH stock was acquired by a variety of institutional investors in the last quarter, including Coatue Management LLC, Polar Capital Holdings Plc, Fred Alger Management LLC, Orbimed Advisors LLC, Capital International Investors, Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., and Franklin Resources Inc..
View insider buying and selling activity for Guardant Health or or view top insider-buying stocks.

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GH stock can currently be purchased for approximately $120.94.

Guardant Health has a market capitalization of $12.23 billion and generates $286.73 million in revenue each year. The company earns $-253,780,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

Guardant Health employs 864 workers across the globe.

The official website for Guardant Health is www.guardanthealth.com.

Guardant Health is headquartered at 505 PENOBSCOT DR., REDWOOD CITY CA, 94063.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887 or via email at [email protected]